ArriVent BioPharma
AVBP
10.52
-0.74
-6.57%
ArriVent BioPharma
US · AVBP
#3057 by market cap
Listed 2024
10.52
-0.74
-6.57%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $29Market Newswire · 2026/10/20
-
Rating change
Clear Street Maintains ArriVent BioPharma(AVBP.US) With Buy RatingMarket Newswire · 2026/10/26
-
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $23Market Newswire · 2026/11/10
-
Rating change
Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)TipRanks · 2026/9/15
-
Rating change
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $21Market Newswire · 2026/10/27
-
Rating change
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $27Market Newswire · 2026/10/8
-
Rating change
ArriVent BioPharma, Inc. (AVBP) Gets a Buy From GuggenheimTipRanks · 2026/9/15
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)TipRanks · 2026/9/15
-
Rating change
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $25Market Newswire · 2026/10/27
-
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/11/12
-
Rating change
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy RatingMarket Newswire · 2026/9/16
-
Rating change
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $30Market Newswire · 2026/10/27
-
Rating change
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $29Market Newswire · 2026/10/7
-
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/11/10
-
Rating change
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $20Market Newswire · 2026/10/7
-
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $27Market Newswire · 2026/10/28
-
Rating change
Analysts' Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)TipRanks · 2026/10/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB), Nuvation Bio (NUVB) and ArriVent BioPharma, Inc. (AVBP)TipRanks · 2026/9/15
-
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $22 to $27Market Newswire · 2026/11/11
-
Rating change
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $45Market Newswire · 2026/9/15
-
Rating change
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47Market Newswire · 2026/8/17
-
Rating change
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50Market Newswire · 2026/8/14
-
Rating change
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/8/15
-
BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/10/27
-
Rating change
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Alterity Therapeutics (ATHE)TipRanks · 2026/8/13
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ArriVent BioPharma discussion 0 comments